CTOs on the Move

Kindeva Drug Delivery

www.kindevadd.com

 
Kindeva is a global force in combination drug delivery and manufacturing. Leveraging more than 100 years of innovation, Kindeva provides unrivaled expertise at every stage of pulmonary & nasal, injectable, and transdermal therapy development and manufacturing. Whether determining ideal delivery and dosage or scaling sterile manufacturing and fill-finish operations, every solution is backed by extensive technological capabilities, deep regulatory knowledge, and nine state-of-the-art facilities. Kindeva`s proactive, informed solutions minimize risk and maximize confidence from ideation through commercialization, bringing high-quality products to patients in need, faster.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Shanmugasundaram Sathish
VP, Digital and Enterprise Applications Profile
Marjorie Nehring
Associate Director of Information Technology - Quality and Manufacturing Applications Profile

Similar Companies

TYRX

TYRX is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anne Arundel Dermatology

With modern, attractive clinical offices in Annapolis, Glen Burnie, Hagerstown, Prince Frederick, Leonardtown, Kent Island, and Easton, 19 board certified physicians, 7 physician assistants, 2 certified nurse practitioners, a full service cosmetic lase...

Fuse Medical

Fuse Medical, Inc., formerly Golf Rounds.com, Inc., is engaged in marketing, distributing and selling internal fixation, bone materials, biologics, tissues, surgical and other related surgical products. The Company operates through medical products and...

Bioniche Pharma USA

Bioniche Pharma USA LLC is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.